How to cite item

Osimertinib as first-line treatment of EGFR mutant advanced nonsmall- cell lung cancer

   
@article{TLCR16634,
	author = {Chong-Kin Liam},
	title = {Osimertinib as first-line treatment of  EGFR  mutant advanced nonsmall- cell lung cancer},
	journal = {Translational Lung Cancer Research},
	volume = {6},
	number = {Suppl 1},
	year = {2017},
	keywords = {},
	abstract = {The epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) gefitinib, erlotinib and afatinib are currently recommended for first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR-TKI-sensitizing mutations (EGFRm) (1,2). However, after a period of 9 to 11 months of treatment, acquired resistance to these first- and secondgeneration EGFR-TKIs inevitably develops. In 50–60% of the cases, acquired resistance is due to EGFR T790M mutation, which is the substitution of threonine with methionine at amino acid position 790, EGFRT790M (3,4).},
	issn = {2226-4477},	url = {https://tlcr.amegroups.org/article/view/16634}
}